A progressive disease that destroys memory and other important mental functions.
- Chronic and progressive neurodegenerative disorder
5.8 million Americans are living with Alzheimer’s today
- A key component of a diagnostic assessment is self-reporting about symptoms
- A doctor administers a test to assess memory and thinking skills
- Other tests are used to rule out similar possibilities
Patients of Alzheimer's Disease are currently segmented into two groups based on the severity of the disease:
Razadyne (galantamine) “modest”
Exelon (rivastigmine) “significant enough”
Aricept (donepezil) “improvement without persistence”
Namenda (memantine) “positive effect”
Namzaric (memantine HCl and donepezil HCl) “improvement in cognition”
Monthly Price ($)
Degree of Progression
Patients of Alzheimer's Disease can be segmented based by age and gender.
Patients of Alzheimer's Disease can be segmented based on geography and future growth.
MARKET FOR ALZHEIMER'S DISEASE
Addressable market of 5.8 million people X $350,174 lifetime value per customer
GROWTH OF DISEASE MODIFYING THERAPY
Potentially identifying biomarkers (besides amyloid plaques) that indicate efficacy of DMTs
- A burden of proof necessary to bring the extended population into DMT sphere of treatment
More sensitive clinical assessment tools
Right timing for treatment
Continued support from investment vehicles for new treatment approaches
Drug development for earlier stages of disease progression
Increased reliance on biomarkers to identify/ market treatments
Prevalence/Cost is going to keep increasing
Better access to healthcare → Better diagnosis
Higher life expectancy → Higher burden of age-related diseases
By 2050 estimate, there will be 103.2 million patients in the world
The total cost of care (including uncompensated care) for patients with Alzheimer’s and other related dementias will hit an estimated $259 billion this year and rise to a staggering $1.1 trillion by 2050. Focus on Research and Development
Focus on Research and Development
Brain imaging for early detection
MRI, PET scan, computed tomography, etc.
Clinical trials: Phase II is the hardest
Currently, a limited repertoire of biomarkers of Alzheimer's Disease
None have achieved the status of a surrogate marker that is known to reliably predict clinical outcomes and can be substituted for clinical measures in trials
Increased competition along with accumulated sunk cost and drug failure
Entry of generic drugs and competitive patents
The primary goal of our treatment is to enhance the quality of life and maximize functional performance by improving cognition, mood, and behavior of patients of Alzheimer's disease
Launch Combination of DMT + Symptomatic therapy
Educational and family support programs
There are some inherent market risks and competitive threats.
However, the treatment can solve an unmet need and create tremendous value for the patients in a growing market.